space tech

Houston tech company gets green light from NASA to train commercial astronauts

KBR signed a Space Act Agreement with NASA's Johnson Space Center to provide private astronaut training in NASA facilities. Photo via NASA.gov

For 60 years, Houston-based KBR has supported NASA's astronauts. Now, though a recently signed Space Act Agreement, KBR will also be providing its human spaceflight operation services to commercial companies.

"KBR has pioneered space travel for more than half a century. We will leverage our domain expertise to assist private astronauts with their human spaceflight activities," says Stuart Bradie, KBR President and CEO, in a news release.

The arrangement will include KBR training private astronauts on NASA property — it's the only agreement of its kind. KBR will train for space tasks like operating onboard of the International Space Station, routine operational tasks, health and performance checks, responding to emergencies, and more.

"This historic agreement is a testament to KBR's long standing partnership with NASA. We will continue to work together to propel NASA's mission to fuel a low-Earth orbit economy and advance the future of commercial space," Bradie continues in the release.

Earlier this week, Axiom Space, a Houston-based space tech startup, announced it was selected to design a commercial space flight habitat to be attached to the ISS. KBR is among Axiom's professional partners on the project.

Image---Axiom-modules-connected-to-ISSKBR is one of Axiom Space's partners on its new NASA-sanctioned ISS project. Photo via AxiomSpace.com

The Axiom project includes plans to replace the ISS with a commercially operated space station. The targeted launch date for the commercial destination module is set for late 2024.

Both the Axiom and KBR agreements with NASA are in line with a shift toward commercialization within the space industry. Last June, NASA released its plan to introduce marketing and commercial opportunities to the ISS — with financial expense being a main factory.

"The agency's ultimate goal in low-Earth orbit is to partner with industry to achieve a strong ecosystem in which NASA is one of many customers purchasing services and capabilities at lower cost," reads the release online.

In an interview with InnovationMap last July, NASA Technology Transfer Strategist Steven Gonzalez explains that opening up the space industry to commercial opportunities allows for NASA to focus on research. The government agency doesn't need to worry about a return on investment, like commercial entities have to.

"With the commercial market now, people keep talking about it being a competition, but in reality we need one another," Gonzalez says. "We have 60 years of history that they can stand on and they are doing things differently that we're learning from."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted